Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| a ai3BioCompany profile ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease. ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease. | $48M | Series A | Biotech | United States | Investors | |
| BT Breye Therapeutics develops oral medicines for retinal diseases. | €67.5M | Series A | Biotech | Denmark | Investors | |
| MB MOYOM BiotechCompany profile Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. | Undisclosed | Financing roundUndisclosed | Biotech, Healthtech | China | Investors | |
| W WonderTxCompany profile AI models designed to discover oral medicines for diseases currently treated with injectable drugs. AI models designed to discover oral medicines for diseases currently treated with injectable drugs. | $125K | Seed | Biotech | United States | Investors | |
| P PilgrimCompany profile Develops autonomous biological-threat detection hardware for defense and critical infrastructure. Develops autonomous biological-threat detection hardware for defense and critical infrastructure. | $25M | Seed | Biotech | United States | Investors | |
| RT Rejuvenation TechnologiesCompany profile Rejuvenation Technologies develops targeted mRNA therapies intended to extend telomeres and restore cellular regenerative capacity in age-related disease. Rejuvenation Technologies develops targeted mRNA therapies intended to extend telomeres and restore cellular regenerative capacity in age-related disease. | Undisclosed | InvestmentUndisclosed | Biotech | United States | Investors | |
| EB Everest BiolabsCompany profile Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. | $2.1M | SBIR Direct-to-Phase II grantUndisclosed | Biotech | United States | Investors | |
| KT Kasvu TherapeuticsCompany profile Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. Kasvu Therapeutics develops small-molecule treatments intended to stimulate neuroplasticity without the hallucinogenic effects associated with psychedelic drugs. | €30M | Series A | Biotech | Finland | Investors | |
| UI United ImmunityCompany profile A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. | ¥2.2B | Private financingUndisclosed | Biotech | Japan | Investors Aozora HYBRID Fund IIIFujita TT Impact Fund I +11ITOCHU CorporationJoyo Bank, Ltd.Kobe University Fund IMitsubishi UFJ Life Sciences Fund IIMiyako Kyoto University Innovation Fund IIIMizuho Life Sciences Fund INVCC Fund 10Ono Venture Investment, Inc.Ricoh Biomedical Startup Investment Limited PartnershipSaisei Bioventures L.P.UTEC Fund V Limited Partnership | |
| BB BigHat BiosciencesCompany profile An AI and synthetic-biology platform that designs and engineers antibody therapeutics. An AI and synthetic-biology platform that designs and engineers antibody therapeutics. | $75M | Series CSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.